Navigation Links
ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program

EXTON, Pa. and WEYBRIDGE, England, Dec. 6, 2010 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP).  ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to individual patients until the time that approval is sought in local countries.

Under an NPP, physicians can prescribe investigational or pre-approval products to qualifying patients on an individual basis. Such products can be administered to individual patients who are suffering from serious illnesses and have no other therapeutic options.  Idis will manage the ViroPharma NPP in countries, except the United States, where the products are not yet approved.

Licensed healthcare professionals in countries other than the United States where such ViroPharma products are not yet approved, can access the program at and on the physician section of the ViroPharma Incorporated corporate website (, or can contact Idis directly via telephone at +44(01)1952 824 100, fax +44 (0)1932 824 300, or via email at

"This program was developed for certain patients who have no alternative therapeutic option for their serious diseases," commented Thierry Darcis M.D., vice president, general manager, ViroPharma Europe. "They are in great need of access to investigational therapeutics that have either been approved in other parts of the world or have shown promise in clinical studies, prior to the time that regulatory approval is sought. ViroPharma is dedicated to meeting the needs of patients, and the management of this NPP with our partners Idis is consistent with that goal."

"The named patient program that we have developed for ViroPharma will help ensure access to important therapies for patients with urgent unmet medical needs. Idis will work in close partnership with ViroPharma to manage named patient requests in a way that is reliable, responsible and legal, ensuring the regulatory obligations are met," commented Simon Estcourt, business development director, Idis.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze(R) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

About Idis

Idis is the global long-term partner to pharmaceutical and biotech companies, pharmacies and physicians. Making sure that the patient is at the heart of everything we do, by developing long-term strategic solutions to creating an understanding of and access to medicines around the globe, enhancing life from different perspectives. Idis Named Patient Programmes (NPPs) create access for the benefit of the patient. Corporate headquarter based near central London, Idis has been a strategic partner to the world's top 10 pharmaceutical and biotech companies. For more information on Idis, please visit the website

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):